bumetanide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diuretics, piretanide derivatives	427	28395-03-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: bumetanide bumethanide bufenox	A sulfamyl diuretic. Molecular weight: 364.42 Formula: C17H20N2O5S CLOGP: 3.37 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 118.72 ALOGS: -4.15 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

bumetanide
bumethanide
bufenox

A sulfamyl diuretic.

Molecular weight: 364.42
Formula: C17H20N2O5S
CLOGP: 3.37
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 118.72
ALOGS: -4.15
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	mg	O
1	mg	P
1	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	45 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.46 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.16 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 28, 1983	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure congestive	217.26	12.95	241	24605	92516	53231704
Acute kidney injury	211.07	12.95	403	24443	253465	53070755
Fluid retention	200.72	12.95	181	24665	54220	53270000
Fluid overload	180.65	12.95	129	24717	27702	53296518
Dyspnoea	165.66	12.95	622	24224	585610	52738610
Right ventricular failure	125.51	12.95	85	24761	16758	53307462
Rheumatoid arthritis	115.61	12.95	8	24838	314523	53009697
Pulmonary arterial hypertension	111.48	12.95	96	24750	27026	53297194
Pulmonary hypertension	106.96	12.95	108	24738	37162	53287058
Oedema peripheral	106.23	12.95	241	24605	170546	53153674
Drug ineffective	99.77	12.95	142	24704	817103	52507117
Renal failure	94.36	12.95	185	24661	118267	53205953
Oedema	93.26	12.95	142	24704	74204	53250016
Cardiac failure	91.23	12.95	152	24694	85692	53238528
Body tinea	78.25	12.95	27	24819	1174	53323046
International normalised ratio increased	77.24	12.95	103	24743	47658	53276562
Renal impairment	71.06	12.95	134	24712	83184	53241036
Off label use	65.75	12.95	74	24772	472138	52852082
Atrial fibrillation	65.41	12.95	154	24692	111498	53212722
Infection susceptibility increased	58.68	12.95	27	24819	2510	53321710
Inhibitory drug interaction	58.12	12.95	26	24820	2264	53321956
Hyperkalaemia	54.86	12.95	94	24752	54162	53270058
Pulmonary oedema	54.22	12.95	93	24753	53630	53270590
Impaired quality of life	52.35	12.95	31	24815	4840	53319380
Hypotension	50.50	12.95	243	24603	253833	53070387
Treatment failure	47.89	12.95	3	24843	128400	53195820
Infusion related reaction	47.07	12.95	8	24838	155949	53168271
Purpura	45.77	12.95	39	24807	10814	53313406
Glucose tolerance impaired	44.83	12.95	29	24817	5291	53318929
Joint swelling	43.28	12.95	28	24818	234610	53089610
Death	43.01	12.95	299	24547	356933	52967287
Exposure during pregnancy	40.94	12.95	5	24841	124855	53199365
Gastrointestinal haemorrhage	40.86	12.95	105	24741	80225	53243995
Alopecia	40.60	12.95	30	24816	234553	53089667
Dyspnoea exertional	40.26	12.95	83	24763	54917	53269303
Cellulitis	39.35	12.95	100	24746	75889	53248331
Chronic obstructive pulmonary disease	38.78	12.95	87	24759	60986	53263234
Bradycardia	37.30	12.95	94	24752	70962	53253258
BRASH syndrome	37.11	12.95	10	24836	185	53324035
Cardiac failure acute	36.97	12.95	32	24814	9060	53315160
Hypoxia	36.12	12.95	80	24766	55600	53268620
Drug intolerance	35.92	12.95	26	24820	205467	53118753
Left ventricular failure	35.22	12.95	25	24821	5308	53318912
Contraindicated product administered	34.79	12.95	10	24836	135619	53188601
Therapeutic product effect decreased	34.65	12.95	8	24838	125647	53198573
Transfusion	32.72	12.95	36	24810	13651	53310569
Arthropathy	31.84	12.95	13	24833	141440	53182780
Congestive cardiomyopathy	29.93	12.95	24	24822	6114	53318106
Pleural effusion	29.87	12.95	100	24746	88479	53235741
Dialysis	29.70	12.95	30	24816	10312	53313908
Blood creatinine increased	29.37	12.95	95	24751	82567	53241653
Haemoglobin decreased	28.44	12.95	133	24713	137174	53187046
Respiratory failure	28.34	12.95	107	24739	100405	53223815
Epistaxis	28.16	12.95	83	24763	68627	53255593
Hepatic enzyme increased	27.75	12.95	12	24834	126183	53198037
Gout	26.88	12.95	31	24815	12368	53311852
Weight increased	26.20	12.95	174	24672	204393	53119827
Blood potassium decreased	26.08	12.95	58	24788	40402	53283818
Pain in jaw	25.88	12.95	58	24788	40611	53283609
Drug hypersensitivity	25.78	12.95	53	24793	265189	53059031
Acute respiratory failure	25.05	12.95	49	24797	31209	53293011
Pneumonia	24.77	12.95	294	24552	406875	52917345
Bone density decreased	24.56	12.95	28	24818	11036	53313184
Arthralgia	23.61	12.95	115	24731	439668	52884552
Dehydration	22.62	12.95	145	24701	168265	53155955
Genital infection female	22.06	12.95	6	24840	115	53324105
Oxygen saturation decreased	21.89	12.95	82	24764	76643	53247577
Cardiorenal syndrome	21.71	12.95	9	24837	650	53323570
Therapeutic product effect incomplete	21.36	12.95	8	24838	91776	53232444
Rectal haemorrhage	20.85	12.95	54	24792	41427	53282793
Drug abuse	20.57	12.95	3	24843	65523	53258697
Anaemia	20.57	12.95	208	24638	276510	53047710
Hospitalisation	20.35	12.95	76	24770	70936	53253284
Hyperlipidaemia	19.96	12.95	34	24812	19481	53304739
Orthopnoea	19.94	12.95	19	24827	6085	53318135
Chronic left ventricular failure	19.84	12.95	7	24839	325	53323895
Arteriosclerosis coronary artery	19.80	12.95	22	24824	8432	53315788
Musculoskeletal stiffness	19.79	12.95	17	24829	123351	53200869
Blood urea increased	19.68	12.95	40	24806	26191	53298029
Unevaluable event	19.53	12.95	59	24787	49439	53274781
Blood potassium increased	19.47	12.95	32	24814	17809	53306411
Torsade de pointes	19.42	12.95	27	24819	12978	53311242
Atrial flutter	19.17	12.95	23	24823	9568	53314652
Intentional overdose	19.09	12.95	4	24842	67201	53257019
Poor quality sleep	18.81	12.95	31	24815	17292	53306928
Abdominal distension	18.54	12.95	80	24766	79710	53244510
Paracentesis	18.43	12.95	9	24837	955	53323265
Chronic kidney disease	18.35	12.95	53	24793	43317	53280903
Cardiomegaly	18.19	12.95	31	24815	17769	53306451
Suicide attempt	17.50	12.95	3	24843	58165	53266055
Skin disorder	17.48	12.95	37	24809	24921	53299299
Urine output decreased	17.16	12.95	24	24822	11599	53312621
Asthenia	17.03	12.95	239	24607	343351	52980869
Blood aldosterone abnormal	16.69	12.95	4	24842	45	53324175
Diaphragmatic disorder	16.66	12.95	7	24839	523	53323697
Impaired work ability	16.37	12.95	26	24820	14064	53310156
Generalised oedema	16.37	12.95	27	24819	15072	53309148
Packed red blood cell transfusion	16.12	12.95	11	24835	2192	53322028
Pemphigoid	15.49	12.95	17	24829	6427	53317793
Brain natriuretic peptide increased	15.47	12.95	15	24831	4910	53319310
Wound	15.45	12.95	12	24834	91545	53232675
Lactic acidosis	15.25	12.95	45	24801	37208	53287012
Lung transplant	15.09	12.95	12	24834	3022	53321198
Liver function test abnormal	15.08	12.95	53	24793	48018	53276202
Oxygen consumption increased	14.87	12.95	13	24833	3728	53320492
Blood sodium decreased	14.74	12.95	33	24813	23083	53301137
Claudication of jaw muscles	14.60	12.95	4	24842	79	53324141
Urosepsis	14.49	12.95	27	24819	16583	53307637
Sinusitis	14.47	12.95	36	24810	168528	53155692
Injection site pain	14.41	12.95	19	24827	113372	53210848
Compartment syndrome	14.40	12.95	10	24836	2051	53322169
Discomfort	14.30	12.95	14	24832	95458	53228762
Product use in unapproved indication	14.08	12.95	19	24827	112270	53211950
Right ventricular dysfunction	14.07	12.95	9	24837	1610	53322610
Malignant neoplasm progression	13.92	12.95	8	24838	71533	53252687
Abdominal discomfort	13.52	12.95	55	24791	221007	53103213
Product use issue	13.45	12.95	28	24818	139556	53184664
Diuretic therapy	13.38	12.95	4	24842	109	53324111
Brain stem stroke	13.35	12.95	5	24841	276	53323944
Incarcerated umbilical hernia	13.33	12.95	3	24843	25	53324195
Seizure	13.32	12.95	25	24821	129484	53194736
Drug monitoring procedure not performed	13.30	12.95	6	24840	533	53323687
Injection site erythema	13.19	12.95	10	24836	77239	53246981
Pain	13.16	12.95	194	24652	588204	52736016
Subacute cutaneous lupus erythematosus	13.15	12.95	10	24836	2358	53321862
Hypersensitivity	13.14	12.95	52	24794	210613	53113607

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	208.04	13.32	513	19374	292955	32200684
Cardiac failure congestive	172.66	13.32	235	19652	84617	32409022
Cardiac failure	136.12	13.32	219	19668	91454	32402185
Fluid retention	113.08	13.32	108	19779	26442	32467197
Dyspnoea	110.58	13.32	475	19412	361570	32132069
Pulmonary hypertension	82.79	13.32	81	19806	20413	32473226
Oedema peripheral	67.46	13.32	187	19700	113904	32379735
Fluid overload	67.30	13.32	71	19816	19550	32474089
Pulmonary arterial hypertension	45.72	13.32	42	19845	9779	32483860
Drug ineffective	45.59	13.32	105	19782	383372	32110267
Oedema	44.05	13.32	90	19797	45057	32448582
Venous pressure jugular increased	43.73	13.32	17	19870	787	32492852
Right ventricular failure	40.97	13.32	37	19850	8426	32485213
Renal failure	39.59	13.32	175	19712	134303	32359336
Blood ketone body increased	37.94	13.32	13	19874	418	32493221
Glomerular filtration rate decreased	36.38	13.32	42	19845	12769	32480870
Blood potassium increased	36.29	13.32	48	19839	16756	32476883
International normalised ratio increased	33.61	13.32	85	19802	48950	32444689
Toxicity to various agents	33.19	13.32	36	19851	178005	32315634
Hyperkalaemia	31.43	13.32	104	19783	69646	32423993
Hypotension	30.38	13.32	231	19656	215879	32277760
Renal impairment	30.38	13.32	124	19763	91848	32401791
Venous pressure jugular decreased	29.68	13.32	7	19880	54	32493585
Peripheral swelling	29.11	13.32	100	19787	68245	32425394
Hepatic cytolysis	28.29	13.32	30	19857	8303	32485336
Cardiac failure chronic	28.08	13.32	28	19859	7212	32486427
Gastrointestinal haemorrhage	27.79	13.32	116	19771	86766	32406873
Ventricular tachycardia	27.38	13.32	53	19834	25503	32468136
Off label use	27.38	13.32	96	19791	306224	32187415
Febrile neutropenia	27.27	13.32	20	19867	119546	32374093
Completed suicide	26.03	13.32	12	19875	92505	32401134
Pyrexia	25.54	13.32	105	19782	319863	32173776
Pulmonary oedema	25.48	13.32	74	19813	46193	32447446
Blood pressure systolic decreased	25.43	13.32	21	19866	4242	32489397
Dyspnoea paroxysmal nocturnal	24.93	13.32	14	19873	1503	32492136
Blood creatinine increased	24.50	13.32	120	19767	96012	32397627
Orthopnoea	24.15	13.32	22	19865	5065	32488574
Atrial fibrillation	23.15	13.32	136	19751	116568	32377071
Dyspnoea exertional	23.10	13.32	64	19823	38897	32454742
Neutropenia	22.06	13.32	33	19854	142142	32351497
Pulmonary renal syndrome	21.88	13.32	7	19880	181	32493458
Weight increased	21.72	13.32	105	19782	83558	32410081
Vasculitic rash	21.69	13.32	11	19876	961	32492678
Orthostatic hypotension	21.39	13.32	48	19839	25602	32468037
Dizziness	20.53	13.32	207	19680	209411	32284228
Cardiac failure acute	20.32	13.32	28	19859	10156	32483483
Hepatic cirrhosis	19.41	13.32	36	19851	16773	32476866
Packed red blood cell transfusion	18.69	13.32	12	19875	1642	32491997
Chronic kidney disease	18.34	13.32	60	19827	39915	32453724
Anti-neutrophil cytoplasmic antibody positive vasculitis	18.22	13.32	9	19878	744	32492895
Rheumatoid arthritis	17.64	13.32	3	19884	44541	32449098
Amyloidosis	17.49	13.32	13	19874	2253	32491386
Weight bearing difficulty	16.58	13.32	9	19878	904	32492735
Transitional cell carcinoma	15.97	13.32	12	19875	2115	32491524
Reaction to excipient	15.93	13.32	7	19880	443	32493196
Bradycardia	15.90	13.32	86	19801	71476	32422163
Hypovolaemia	15.64	13.32	23	19864	8854	32484785
Death	15.00	13.32	322	19565	382195	32111444
Treatment failure	14.73	13.32	3	19884	39160	32454479
Hospitalisation	14.57	13.32	64	19823	48907	32444732
Polyuria	14.52	13.32	21	19866	7964	32485675
Suicide attempt	14.24	13.32	3	19884	38241	32455398
Brain natriuretic peptide abnormal	14.07	13.32	6	19881	353	32493286
Sinus bradycardia	14.06	13.32	27	19860	12911	32480728
Abdominal cavity drainage	14.02	13.32	6	19881	356	32493283
Hepatic function abnormal	13.93	13.32	5	19882	44835	32448804
Ascites	13.90	13.32	55	19832	40136	32453503
Haemoglobin decreased	13.58	13.32	122	19765	119549	32374090
Blood urea increased	13.53	13.32	47	19840	32226	32461413
Neutrophil count decreased	13.43	13.32	6	19881	47133	32446506

Pharmacologic Action:

Source	Code	Description
ATC	C03CA02	CARDIOVASCULAR SYSTEM DIURETICS HIGH-CEILING DIURETICS Sulfonamides, plain
ATC	C03CB02	CARDIOVASCULAR SYSTEM DIURETICS HIGH-CEILING DIURETICS Sulfonamides and potassium in combination
ATC	C03EB02	CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION High-ceiling diuretics and potassium-sparing agents
FDA PE	N0000175366	Increased Diuresis at Loop of Henle
FDA EPC	N0000175590	Loop Diuretic
CHEBI has role	CHEBI:35498	diuretics
CHEBI has role	CHEBI:131770	cystic fibrosis transmembrane conductance regulator inhibitors
MeSH PA	D004232	Diuretics
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D049994	Sodium Potassium Chloride Symporter Inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Edema	indication	267038008
Edema due to Hepatic Cirrhosis	indication
Peripheral Edema due to Chronic Heart Failure	indication
Renal Disease with Edema	indication
Pulmonary Edema due to Chronic Heart Failure	indication
Hypertensive disorder	off-label use	38341003	DOID:10763
Hypercalcemia	off-label use	66931009	DOID:12678
Decompensated cardiac failure	off-label use	195111005
Anuria	contraindication	2472002	DOID:2983
Hypocalcemia	contraindication	5291005
Hypovolemia	contraindication	28560003
Hyperuricemia	contraindication	35885006	DOID:1920
Hypokalemia	contraindication	43339004
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Oliguria	contraindication	83128009
Hearing disorder	contraindication	128540005
Hypomagnesemia	contraindication	190855004
Disease of liver	contraindication	235856003	DOID:409
Thrombocytopenic disorder	contraindication	302215000	DOID:1588

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.36	acidic
pKa2	9.88	acidic
pKa3	0.86	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Solute carrier family 12 member 1	Transporter	Q13621	S12A1_HUMAN	INHIBITOR	Ki	7.60	WOMBAT-PK	CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-1	Transporter	P05023	AT1A1_HUMAN		Kd	7.52	WOMBAT-PK
Solute carrier family 12 member 2	Transporter	P55011	S12A2_HUMAN	INHIBITOR	IC50	5.60	IUPHAR
G-protein coupled receptor 35	GPCR	Q9HC97	GPR35_HUMAN	AGONIST	EC50	5.54	IUPHAR

External reference:

ID	Source
4017794	VUID
N0000146155	NUI
D00247	KEGG_DRUG
C0006376	UMLSCUI
CHEBI:3213	CHEBI
CHEMBL1072	ChEMBL_ID
DB00887	DRUGBANK_ID
D002034	MESH_DESCRIPTOR_UI
2471	PUBCHEM_CID
4837	IUPHAR_LIGAND_ID
2943	INN_ID
0Y2S3XUQ5H	UNII
1808	RXNORM
3606	MMSL
4304	MMSL
d00179	MMSL
002312	NDDF
387498005	SNOMEDCT_US
86647004	SNOMEDCT_US
4017794	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0128	TABLET	0.50 mg	ORAL	ANDA	21 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0129	TABLET	1 mg	ORAL	ANDA	21 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0130	TABLET	2 mg	ORAL	ANDA	21 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1412	INJECTION, SOLUTION	0.25 mg	INTRAMUSCULAR	ANDA	20 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8361	TABLET	1 mg	ORAL	ANDA	20 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8362	TABLET	2 mg	ORAL	ANDA	20 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8393	TABLET	1 mg	ORAL	ANDA	21 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8394	TABLET	2 mg	ORAL	ANDA	21 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6007	INJECTION	0.25 mg	INTRAMUSCULAR	ANDA	22 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6008	INJECTION	0.25 mg	INTRAMUSCULAR	ANDA	22 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6161	INJECTION	0.25 mg	INTRAMUSCULAR	ANDA	22 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6162	INJECTION	0.25 mg	INTRAMUSCULAR	ANDA	22 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0540	TABLET	0.50 mg	ORAL	ANDA	22 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0541	TABLET	1 mg	ORAL	ANDA	22 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0542	TABLET	2 mg	ORAL	ANDA	22 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7016	TABLET	1 mg	ORAL	ANDA	21 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	14539-700	TABLET	0.50 mg	ORAL	ANDA	19 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	14539-701	TABLET	1 mg	ORAL	ANDA	19 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	14539-702	TABLET	2 mg	ORAL	ANDA	19 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-831	TABLET	0.50 mg	ORAL	ANDA	18 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-832	TABLET	1 mg	ORAL	ANDA	18 sections
bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-833	TABLET	2 mg	ORAL	ANDA	18 sections
Bumex	HUMAN PRESCRIPTION DRUG LABEL	1	30698-630	TABLET	0.50 mg	ORAL	NDA	21 sections
Bumex	HUMAN PRESCRIPTION DRUG LABEL	1	30698-631	TABLET	1 mg	ORAL	NDA	21 sections
Bumex	HUMAN PRESCRIPTION DRUG LABEL	1	30698-632	TABLET	2 mg	ORAL	NDA	21 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	33261-983	TABLET	1 mg	ORAL	ANDA	20 sections
Bumetanide	Human Prescription Drug Label	1	42799-119	TABLET	0.50 mg	ORAL	NDA AUTHORIZED GENERIC	23 sections
Bumetanide	Human Prescription Drug Label	1	42799-120	TABLET	1 mg	ORAL	NDA AUTHORIZED GENERIC	23 sections
Bumetanide	Human Prescription Drug Label	1	42799-121	TABLET	2 mg	ORAL	NDA AUTHORIZED GENERIC	23 sections
Bumetanide	HUMAN PRESCRIPTION DRUG LABEL	1	43353-288	TABLET	1 mg	ORAL	ANDA	21 sections